BioSpace News Archive

AV-101 is a Proprietary Inhaled Version of Imatinib, Which Has Proven Efficacy Treating PAH; Aerovate Was Founded and Seeded by RA Capital Management; Series A is Led by Sofinnova Investments; Includes New Investors Atlas Venture, Cormorant Asset Management, Surveyor Capital and Osage University Partners

Lankenau Heart Institute, part of Main Line Health, has named Basel Ramlawi, MD, the System Chief of Cardiac Surgery for Main Line Health and co-director of the Lankenau Heart Institute.

QOL Medical, LLC announced that PLoS ONE has published the results from a study of hypomorphic SI genetic variants known to cause Congenital Sucrase-Isomaltase Deficiency.

University of Minnesota’s Dr. Sara Hamman Osum Recognized with the 2020 Boehringer Ingelheim Veterinary Graduate Award and Megan Fahey from Cornell University Receives the 2020 Boehringer Ingelheim Veterinary Research Scholar Award

Blue Sprig Pediatrics, Inc. announces that it has acquired the assets of the Carmel, CA based Aptitude Habilitation Services.

Group Seeks Partner for Funding, Logistics Support in Sending Modified Sleep Apnea Devices to Latin America, the Caribbean, Africa and throughout the U.S.

Gilead Sciences (Gilead) has recently come under fire for allegedly withholding a safer, more efficient drug than the highly toxic tenofovir disoproxil fumarate (TDF).

INVO Bioscience, Inc. (OTCQB: INVO), (“the Company”, “INVO”) a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, is scheduled to participate in a virtual presentation at the August 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, August 19, 2020

GVB Biopharma, a pharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it has established the process and infrastructure for producing medicinal products from cannabigerol (CBG)

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2020 after the close of the market on Thursday, August 13, 2020.